Document Detail

Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia.
MedLine Citation:
PMID:  18380409     Owner:  NLM     Status:  MEDLINE    
In recent years, sialic acid is considered to be a possible marker for cardiovascular diseases. The aim of this study was to investigate the effect of two different treatment periods of fenofibrate (CAS 49562-28-9) on serum, heart and liver sialic acid levels in experimental hypercholesterolemia. Serum, heart and liver total sialic acid levels were determined by Warren's thiobarbituric acid (TBA) method and serum lipid levels by commercial kits at the end of the fenofibrate treatment for 3 and 6 weeks. Fenofibrate treatment reduced serum total sialic acid levels significantly in the control and hypercholesterolemic groups at the end of the 3rd week and only in the control group at the end of the 6th week. Serum sialic acid levels of fenofibrate-treated hypercholesterolemic rats in the 6-week period were significantly higher than those in the 3-week period. Neither the hypercholesterolemic diet nor fenofibrate had any significant effect on heart and liver sialic acid levels. In conclusion, decreased serum sialic acid levels in control and hypercholesterolemic groups by fenofibrate short-term treatment may contribute to the decreased risk of cardiovascular diseases that accompanies the hypercholesterolemic complications. The decreased serum sialic acid levels further indicate the clinical efficacy of fenofibrate as an anti-inflammatory agent.
Leyla Koç Oztürk; Ayşen Yarat; Nesrin Emekli
Related Documents :
7085639 - Purification and macromolecular properties of a sialic acid-specific lectin from the sl...
165879 - Independence of sialic acid levels in normal and malignant growth.
11511809 - Characterisation of the enzymatic 4-o-acetylation of sialic acids in microsomes from eq...
8550119 - Administration of the plasticizer di (2-ethylhexyl) phthalate alters glycoconjugate pro...
18722069 - Antibody-based enzyme-linked lectin assay (abella) for the sialylated recombinant human...
20024109 - Sialidase substrate specificity studies using chemoenzymatically synthesized sialosides...
3769399 - The exchange of blood-borne amino acids in the leg during abdominal surgical trauma: ef...
9543249 - Amino acid release during volume regulation by cardiac cells: cellular mechanisms.
124319 - Hepatic mitochondrial function in ketogenic states. diabetes, starvation, and after gro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  57     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  2007  
Date Detail:
Created Date:  2008-04-02     Completed Date:  2008-05-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  770-6     Citation Subset:  IM    
Department of Biochemistry, Faculty of Dentistry, Marmara University, Nisantasi, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / therapeutic use*
Body Weight
Cholesterol / blood
Cholesterol, LDL / blood
Hypercholesterolemia / blood,  drug therapy*
Liver / metabolism
Myocardium / metabolism
N-Acetylneuraminic Acid / blood,  metabolism*
Organ Size / drug effects
Procetofen / therapeutic use*
Rats, Wistar
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, LDL; 131-48-6/N-Acetylneuraminic Acid; 49562-28-9/Procetofen; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interrelations between diabetes therapy, self-monitoring of blood glucose, blood glucose and non-fat...
Next Document:  Synthesis and analgesic and anti-inflammatory activity of ethyl (6-substituted-3 (2H)-pyridazinone-2...